Literature DB >> 14631577

[Diabetic cardiopathy: pathogenesis, diagnosis and therapy].

C Tschöpe1, H P Schultheiss.   

Abstract

Diabetes mellitus is one of the most widespread metabolic diseases in Western industrial countries with increasing prevalence due to a progressively aging population that is also characterized by increasing obesity and a sedentary life style. Cardiovascular conditions are the major prognostic complications of diabetes. Cardiologically, diabetic cardiopathy may become manifest on different structural and functional levels of the heart. Disorders may involve the micro- and macrocirculation (angiopathy), ventricular function (cardiomyopathy) and the intracardial nervous system (autonomous neuropathy). The following survey summarizes the cardiovascular risk with particular attention to the pathogenesis, diagnostics and therapy of diabetes mellitus related coronary disease and diabetic cardiomyopathy.

Entities:  

Mesh:

Year:  2003        PMID: 14631577     DOI: 10.1007/s00108-003-0947-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  46 in total

1.  No evidence for systolic or diastolic left ventricular dysfunction at rest in selected patients with long-term type I diabetes mellitus.

Authors:  M Romanens; S Fankhauser; B Saner; L Michaud; H Saner
Journal:  Eur J Heart Fail       Date:  1999-06       Impact factor: 15.534

2.  Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

Authors:  Eva Lonn; Salim Yusuf; Byrcon Hoogwerf; Janice Pogue; Qilong Yi; Bernard Zinman; Jackie Bosch; Gilles Dagenais; Johannes F E Mann; Hertzel C Gerstein
Journal:  Diabetes Care       Date:  2002-11       Impact factor: 19.112

Review 3.  New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment.

Authors:  Michael R Zile; Dirk L Brutsaert
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

4.  Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.

Authors:  E Regar; P W Serruys; C Bode; C Holubarsch; J L Guermonprez; W Wijns; A Bartorelli; C Constantini; M Degertekin; K Tanabe; C Disco; E Wuelfert; M C Morice
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

7.  Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model.

Authors:  K Mizushige; L Yao; T Noma; H Kiyomoto; Y Yu; N Hosomi; K Ohmori; H Matsuo
Journal:  Circulation       Date:  2000-02-29       Impact factor: 29.690

8.  Parasympathetic neuropathy associated with left ventricular diastolic dysfunction in patients with insulin-dependent diabetes mellitus.

Authors:  R B Willenheimer; L R Erhardt; H Nilsson; B Lilja; S Juul-Möller; G Sundkvist
Journal:  Scand Cardiovasc J       Date:  1998       Impact factor: 1.589

9.  Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

Authors: 
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

10.  Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.

Authors:  Fumitaka Kuwahara; Hisashi Kai; Keisuke Tokuda; Mamiko Kai; Akira Takeshita; Kensuke Egashira; Tsutomu Imaizumi
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

View more
  3 in total

1.  Cardio-Protective Role of Gingerol along with Prominent Anti-Diabetic Cardiomyopathy Action in A Streptozotocin-Induced Diabetes Mellitus Rat Model.

Authors:  Li-Ya Yu; Wen-Lei Shi; Xin-GuiGuo Guo
Journal:  Cell J       Date:  2017-08-19       Impact factor: 2.479

Review 2.  Catalpol in Diabetes and its Complications: A Review of Pharmacology, Pharmacokinetics, and Safety.

Authors:  Ying Bai; Ruyuan Zhu; Yimiao Tian; Rui Li; Beibei Chen; Hao Zhang; Bingke Xia; Dandan Zhao; Fangfang Mo; Dongwei Zhang; Sihua Gao
Journal:  Molecules       Date:  2019-09-11       Impact factor: 4.411

3.  Gender disparities in diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the DIANA study.

Authors:  Heike U Krämer; Elke Raum; Gernot Rüter; Ben Schöttker; Dietrich Rothenbacher; Thomas Rosemann; Joachim Szecsenyi; Hermann Brenner
Journal:  Cardiovasc Diabetol       Date:  2012-07-27       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.